Scientists develop antivenom cocktail against Indian King Cobra
SCIENTISTS have developed an experimental next-generation antivenom that could offer protection against the venom of several cobra and king cobra species found across India, potentially opening the door to safer and more broadly effective treatments for one of the country's deadliest public health emergencies.
Snakebite envenoming kills more than 1,00,000 people globally every year, with India accounting for nearly half of those deaths. Yet the antivenoms currently used to treat snakebite victims face major limitations, including inconsistent effectiveness against venoms from snakes living in different geographical regions.
Most conventional antivenoms are produced using antibodies derived from horse plasma. While they have saved countless lives, their effectiveness can vary depending on the snake species and geographical origin of the venom.
They can also cause allergic reactions and may not effectively neutralise the wide variety of toxins found in venom from different snake populations.
The scientists created a cocktail designed to neutralise three major groups of toxins commonly found in the venom of cobras and king cobras in India: alpha-neurotoxins, cytotoxins and phospholipases A2. These toxins can cause paralysis, tissue damage and other life-threatening effects following a snakebite.
In experiments involving mice, the five-nanobody cocktail prevented deaths caused by venom from the monocled cobra (Naja kaouthia), the two king cobra species found in India, Ophiophagus kaalinga and Ophiophagus hannah, and spectacled cobras (Naja naja) from populations across the country.
The treatment was tested against venoms collected from different regions, including the Western Ghats and Northeast India, suggesting that it may have the potential to overcome one of the biggest challenges facing traditional antivenoms: regional variations in snake venom.
The findings demonstrate the possibility of developing broad-spectrum recombinant antivenoms capable of offering protection across large geographical regions.
Researchers say nanobody-based treatments could eventually provide a safer and more adaptable alternative to conventional horse-derived antivenoms. Because the antibodies can be produced using recombinant technology, scientists may also be able to tailor them more precisely to target the medically important toxins found in different regions.
However, the researchers cautioned that the results are based on experiments in mice. Further studies, including extensive safety testing and clinical trials in humans, will be needed before such an antivenom can become available for treating snakebite victims.
Still, the study offers fresh hope that advances in biotechnology could help transform snakebite treatment in India, where thousands continue to die every year from venomous snakebites.
